Alume Biosciences Announces Publication of Data Examining First-in-Human Use of Bevonescein to Illuminate Nerves in Nature Communications
'These data support our belief that bevonescein can help make surgery more precise by allowing surgeons to see nerves more clearly."
Bevonescein is a novel fluorescent visualization drug designed to selectively illuminate nerves during surgery, helping to prevent inadvertent nerve injury and is currently being evaluated in ongoing Phase 3 clinical trials.
'Currently, many head and neck surgeries result in nerve injuries, which can be catastrophic for the patients,' said Eben L. Rosenthal, MD, Barry Baker Professor and Chair of the Department of Otolaryngology–Head and Neck Surgery at Vanderbilt University Medical Center and study senior author. 'This first-in-human data demonstrate the safety of bevonescein and its potential to enhance nerve visualization in real time. It's especially promising to see improvements in nerve conspicuity at the optimal dose.'
Key Findings:
Fluorescence Superiority: Bevonescein provided enhanced nerve visualization with higher nerve conspicuity scores in fluorescent compared to white light. All participants demonstrated improved visible nerve length; 57% showed more than 20% improvement.
Optimal Dose Defined: The optimal treatment dose of bevonescein was 500mg.
Favorable Safety Profile: No dose-limiting toxicities or infusion reactions occurred. No surgeries were delayed or canceled due to the study drug.
'These data support our belief that bevonescein can help make surgery more precise by allowing surgeons to see nerves more clearly,' said Quyen Nguyen, MD, PhD, Founder and CEO of Alume Biosciences. 'When Roger Tsien and I started work on bevonescein, our vision was to translate his Nobel Prize-winning discoveries regarding fluorescence into tools that directly improve surgical outcomes. This milestone brings us closer to that goal.'
'With the growing adoption of fluorescence guidance in surgery, it's exciting to see this technology now applied to nerve identification,' said Ryan Orosco, MD, Associate Professor, University of New Mexico and the study's co-lead author. 'Bevonescein represents a paradigm shift in how we identify nerves during surgery, and ultimately how we improve patient outcomes.'
Study Overview
The dose-defining and dose-timing clinical trial enrolled 27 adults undergoing elective head and neck surgery including parotidectomy, thyroidectomy and cervical neck dissections. Participants received intravenous bevonescein at varying doses to assess safety, pharmacokinetics, and optimal visualization timing. Surgical visualization of bevonescein-enabled nerve fluorescence was performed using the Zeiss Tivato surgical microscope with Yellow 560. Surgeons assessed nerve visualization using 4-point Likert scale that measured conspicuity, visible nerve length, and delineation of branching.
About Bevonescein (ALM-488)
Bevonescein is Alume's lead compound—a targeted fluorescent peptide-dye conjugate that binds to nerve tissue, enabling intraoperative nerve visualization. It is currently in Phase 3 clinical trials and is planned for New Drug Application (NDA) submission to the U.S. Food and Drug Administration in 2026.
About Alume Biosciences
Alume Biosciences is a biotechnology company pioneering nerve-targeted drugs to enhance surgical precision and preserve nerve function. Founded on a lead candidate co-invented by late Nobel Laureate Dr. Roger Tsien, Alume is committed to translating cutting-edge science into practical tools for surgeons and better outcomes for patients. Learn more at alumebiosciences.com and LinkedIn.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
knownwell Strengthens Regional Footprint, Opens Second Clinic in the Greater Boston Area
The Company Unveils its Seventh New Weight-Inclusive Care Location in the Last Year, Increasing Patient Population by Nearly 400% BOSTON, August 19, 2025--(BUSINESS WIRE)--knownwell, an in-person and virtual weight-inclusive primary care and metabolic health company that opened its flagship clinic in Needham, Massachusetts in 2023, announces the deepening of its physical presence in the greater Boston area. As the company continues to increase access to weight-inclusive care across the country, the opening of a new clinic will provide additional opportunities for in-person engagement with locally based patients near Woburn, Massachusetts. The news comes on the heels of knownwell opening seven new clinics in the last year, including one in Dallas and six in Chicago, to provide in-person care in the Midwest and South Central regions. It also follows the company's launch of virtual metabolic care to patients in all 50 U.S. states. Today, more than half of adults in Massachusetts are affected by overweight or obesity. In Woburn alone, 1 in 4 adults has obesity. With few options for comprehensive metabolic care in the area, the addition of a new local clinic comes at a pivotal time to support those in need. "Boston has always held a special place in our story – it is where our mission began, and where we proved that weight-inclusive care can change lives," said Brooke Boyarsky Pratt, CEO and Co-Founder of knownwell. "This expansion isn't just about growth; it's about meeting an urgent need in a community that has inspired us from day one. Expanding our footprint here reflects both the significant need and our dedication to delivering accessible, whole-person care to help more people in Massachusetts achieve lasting health." The Woburn clinic arrives amid the demand for GLP-1 medications surging and the cost of treatment continuing to rise, creating new barriers for patients seeking effective, long-term solutions for obesity and overweight. By growing its presence in Massachusetts, the company aims to bridge this gap, delivering treatment that combines clinical, nutritional, and behavioral support to ensure patients receive the full spectrum of care they need to improve their health and quality of life. "When I moved to Massachusetts decades ago, it was to be part of a movement to treat obesity like the chronic disease it is – with science, compassion, and comprehensive care. This expansion in greater Boston is the next chapter in that mission, with knownwell leading the charge," said Chief Medical Officer and Co-Founder of knownwell, Dr. Angela Fitch. "By increasing access to integrated treatment, we're not just helping individuals improve their health but taking meaningful steps toward reducing obesity rates across the country." With the new opening, knownwell will additionally onboard Dr. Giovanna Leddy, President of the New England Obesity Society, as the new Market Medical Director, overseeing both the Woburn and Needham practices. Dr. Leddy serves as the Associate Director of the Social Justice Pathway within the Internal Medicine Residency Program at Beth Israel Deaconess Medical Center and currently practices Obesity Medicine at Atrius Health. She is also a Clinical Instructor in Medicine at Harvard Medical School. knownwell is on a mission to make weight-inclusive healthcare more accessible. It offers full-coverage care, including metabolic health services, comprehensive primary care, nutrition counseling, and behavioral health services online and in person, and accepts insurance. To learn more about knownwell, visit ABOUT KNOWNWELL: knownwell is built for the millions of Americans who have been told that their weight is the problem, regardless of their unique health concerns. Stigmatizing patients does not promote wellness, and in fact, leads to worse health outcomes. knownwell practices evidence-based medicine that supports a patient's unique goals, creating a healthcare home for patients with overweight and obesity. To learn more, visit View source version on Contacts Karalyn HooverSolCommsknownwell@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
3 hours ago
- Business Wire
Innovaccer Launches Flow Auth to Automate Prior Authorizations, Designed to Deliver 5x ROI
SAN FRANCISCO--(BUSINESS WIRE)--Innovaccer Inc., a leading healthcare AI company, today announced the launch of Flow Auth, an AI-powered prior authorization solution, that is part of Flow by Innovaccer, the company's revenue cycle performance platform. Flow Auth automates the entire prior authorization workflow, from detecting authorization needs to generating appeal letters, with intelligent exception handling that keeps humans in the loop, helping healthcare organizations accelerate care delivery and optimize revenue capture. With Flow Auth, Innovaccer projects an estimated 50% reduction in clinician time spent on prior authorizations and a twofold increase in staff productivity, with projected ROI of up to 5x through efficiency gains and reduced denials based on initial implementations 1. The AMA's 2024 Prior Authorization Physician Survey shows the scale of the problem, 94 percent of physicians say prior authorization delays care, 27 percent report requests are often or always denied, and 89 percent link the process to increased burnout. Flow Auth tackles these challenges directly by automating the workflow end to end, reducing delays, lowering denial rates, and easing the administrative load on clinical teams. Currently, according to a CAQH report, about 30% prior authorizations can be sent electronically; the remaining majority are processed through fax, payer portals, or phone calls, creating inefficiencies that impact both patient outcomes and health system performance. Flow Auth leverages an end-to-end automation framework powered by a seamlessly integrated ecosystem of AI Agents. It streamlines relevant stages of the PA process, from eligibility verification and submission to appeals, while adhering to payer-specific guidelines. This enables faster approvals, reduced revenue delays, and lowers manual workload, enabling submissions to meet requirements the first time. Key features include: Proactive PA Detection: Automatically identifies when prior authorization is required when an order is placed in the EHR, based on payer-specific criteria. Integrated Payer Rules: References the latest medical necessity guidelines for each payer, ensuring accurate submissions the first time. Payer-Ready Packet Creation: Automatically assembles relevant clinical documentation, notes, labs, and imaging, flagging any missing items, and organizing them in the format payers expect. Full-Spectrum Submission: Sends packets using the full range of payer connectivity options, APIs, portals, or fax. Real-Time Tracking: Monitors authorization status and provides updates within the clinical workflow. Automated Appeals Drafting: Helps streamline appeals by drafting a letter for denied requests using historical outcomes and payer-specific policies, auto-filling required clinical details. Flow Auth is designed keeping in mind the current systems in the marketplace, making it highly compatible with the existing systems. It integrates seamlessly with major EHRs and payers. Innovaccer has the ability to add new payers based on customer needs so prior authorizations can be automated across their entire payer mix. 'Prior authorization should never stand between a patient and the care they need,' said Abhinav Shashank, cofounder and CEO at Innovaccer. 'Every day lost to paperwork is a day a patient waits in uncertainty. Flow Auth changes that by removing the administrative roadblocks substantially. It keeps the process invisible to patients, effortless for providers, and always aligned with the latest payer requirements. This is about giving clinicians back their time and patients back their speed to care.' The solution supports a wide range of major payers, including Humana, UnitedHealthcare, Blue Cross Blue Shield, Anthem, Aetna, and others, enabling broad coverage and streamlined workflows across diverse payer networks. About Innovaccer Innovaccer activates the flow of healthcare data, empowering providers, payers, and government organizations to deliver intelligent and connected experiences that advance health outcomes. The Healthcare Intelligence Cloud equips every stakeholder in the patient journey to turn fragmented data into proactive, coordinated actions that elevate the quality of care and drive operational performance. Leading healthcare organizations like CommonSpirit Health and Banner Health trust Innovaccer to integrate a system of intelligence into their existing infrastructure, extending the human touch in healthcare. For more information, visit 1 Based on internal estimates
Business Wire
3 hours ago
- Business Wire
Susan G. Komen ® To Host MORE THAN PINK Walk in Milwaukee This September
MILWAUKEE--(BUSINESS WIRE)-- Susan G. Komen ®, the world's leading breast cancer organization, will convene breast cancer survivors, those living with metastatic breast cancer (MBC) and supporters at the 2025 Susan G. Komen Wisconsin MORE THAN PINK Walk. This impactful event unites our community and raises money for the mission of Komen, supporting those affected by breast cancer. We look forward to bringing together the Wisconsin community this fall and uniting around our goal of creating a world where we do not lose another life to this disease. Share Komen aims to raise over $500,000 at the Wisconsin MORE THAN PINK Walk, generating critical funds that allow Komen to continue its investment in lifesaving work across the country, including promising research that will allow people to live longer lives with better outcomes. This event also funds Komen's Patient Care Center, a trusted, go-to source for timely, accurate breast health and breast cancer information, support and resources, as well as the work of Komen's Center for Public Policy to drive state and federal policies that invest in critical programs and ensure streamlined access to affordable, high-quality breast health care. WHEN: Sunday, September 28, 2025 WHERE: Henry Maier Festival Park, 200 N Harbor Dr, Milwaukee, WI 53202 DETAILS: 7:30 a.m. Site Opens – 9:00 a.m. Opening Ceremony WHY IT MATTERS: Breast cancer affects 1 in 8 women in the U.S. and 1 in 1,000 men in their lifetime. In 2025 alone, an estimated 316,950 women in the U.S. will be diagnosed with breast cancer and 42,170 women will die from the disease. Approximately 2,800 men will be diagnosed with breast cancer and 510 will die from it. However, some experts say one-third of breast cancer deaths in the U.S. could be prevented with universal access to modern treatments. In Wisconsin, approximately over 5,900 people will be diagnosed with breast cancer and 470 will die from the disease this year. Susan G. Komen provides direct support to Wisconsinites through its Patient Care Center. In fiscal year 2025, Komen provided assistance to 550 patients, including over $143,000 in financial assistance to eligible people in active treatment or living with metastatic breast cancer. 'The work Komen does for people with breast cancer, survivors and those with increased risk of breast cancer is not possible without the Wisconsin MORE THAN PINK Walk and the critical money we raise from our generous supporters,' said Nikki Panico, executive director Wisconsin at Susan G. Komen. 'We look forward to bringing together the Wisconsin community this fall and uniting around our goal of creating a world where we do not lose another life to this disease.' This year's Komen Wisconsin MORE THAN PINK Walk is made possible by the following sponsors: Ford Dealers of Wisconsin, Foxconn, WaterStone Bank, SC Johnson, Campbell's, and Gruber Law. Bank of America is the national presenting sponsor and Lilly, Natera, and Novartis are national series sponsors for the MORE THAN PINK Walk and Race for the Cure events. About Susan G. Komen ® Susan G. Komen ® is the world's leading nonprofit breast cancer organization, working to save lives and end breast cancer forever. Komen has an unmatched, comprehensive 360-degree approach to fighting this disease across all fronts and supporting millions of people in the U.S. and in countries worldwide. We advocate for patients, drive research breakthroughs, improve access to high-quality care, offer direct patient support and empower people with trustworthy information. Founded by Nancy G. Brinker, who promised her sister, Susan G. Komen, that she would end the disease that claimed Suzy's life, Komen remains committed to supporting those affected by breast cancer today, while tirelessly searching for tomorrow's cures. Visit or call 1-877 GO KOMEN. Connect with us on social at
